Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alphamab and 3D Medicines Out-License PD-L1 to India’s Glenmark

publication date: Jan 25, 2024

Jiangsu Alphamab Biopharma and its partner 3D Medicines of Beijing announced an out-licensing agreement for their approved subcutaneous injection PD-L1 inhibitor, envafolimab, with Glenmark Specialty SA (GSSA) of India. GSSA will have exclusive rights to develop, register, commercialize envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. In 2021, envafolimab was the global-first subcutaneous injection PD-L1 inhibitor approved. It was indicated as a second-line therapy for microsatellite instability-high (MSI-H) or deficient MisMatch repair (dMMR) solid tumors. Over 30,000 patients in China been treated with envafolimab. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here